(6R,14R,15R,16R)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: (6R,14R,15R,16R)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
• 化学式: C₂₅H₃₅NO₄
• 分子量: 413.5
• InChiKey: YOYLLRBMGQRFTN-OVYMLYFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  71
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• 1,3-DIOXANOMORPHIDES AND 1,3-DIOXANOCODIDES
  申请人：Rhodes Technologies

  公开号：EP2888267B1

  公开（公告）日：2017-01-18
• [EN] 1,3-DIOXANOMORPHIDES AND 1,3-DIOXANOCODIDES<br/>[FR] 1,3-DIOXANOMORPHIDES ET 1,3-DIOXANOCODIDES
  申请人：RHODES TECHNOLOGIES

  公开号：WO2014033530A1

  公开（公告）日：2014-03-06

  The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein G, R2-R5, and (a) are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) as synthetic intermediates or to treat disorders responsive to the modulation of one or more opiopid receptors. Certain compounds of the present invention are especially useful for treating pain.